Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ATXI | Avenue Therapeutics, Inc.

Index	-	P/E	-	EPS (ttm)	-2.19	Insider Own	18.50%	Shs Outstand	7.76M	Perf Week	-31.23%
Market Cap	4.67M	Forward P/E	-	EPS next Y	-	Insider Trans	102.33%	Shs Float	6.72M	Perf Month	-36.94%
Income	-11.60M	PEG	-	EPS next Q	-0.26	Inst Own	1.60%	Short Float / Ratio	0.14% / 0.15	Perf Quarter	-49.55%
Sales	-	P/S	-	EPS this Y	50.60%	Inst Trans	30.94%	Short Interest	0.01M	Perf Half Y	-45.70%
Book/sh	-0.69	P/B	-	EPS next Y	-	ROA	-265.30%	Target Price	32.00	Perf Year	-82.21%
Cash/sh	0.20	P/C	2.92	EPS next 5Y	-	ROE	-	52W Range	0.61 - 16.65	Perf YTD	-50.85%
Dividend	-	P/FCF	-	EPS past 5Y	43.30%	ROI	-	52W High	-96.58%	Beta	-0.34
Dividend %	-	Quick Ratio	0.20	Sales past 5Y	-	Gross Margin	-	52W Low	-6.71%	ATR	0.07
Employees	2	Current Ratio	0.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	24.27	Volatility	12.49% 8.42%
Optionable	No	Debt/Eq	-	EPS Q/Q	-24.90%	Profit Margin	-	Rel Volume	1.70	Prev Close	0.61
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 10 AMC	Payout	-	Avg Volume	64.11K	Price	0.57
Recom	2.00	SMA20	-27.24%	SMA50	-39.99%	SMA200	-49.33%	Volume	108,943	Change	-7.15%

Sep-05-23 08:30AM	Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -6.40%
Aug-14-23 04:01PM	Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-10-23 04:15PM	Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-01-23 08:30AM	Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study (GlobeNewswire)
Jul-27-23 08:30AM	Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) (GlobeNewswire)
08:30AM	Loading…
Jul-25-23 08:30AM	Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol (GlobeNewswire)
May-15-23 04:01PM	Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-12-23 08:30AM	Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Apr-27-23 08:30AM	Avenue Therapeutics to Present at Aegis Capital Virtual Conference (GlobeNewswire)
Apr-17-23 04:01PM	Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol (GlobeNewswire) +5.50%
Mar-30-23 04:10PM	Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:01PM	Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-08-23 04:01PM	Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates (GlobeNewswire)
Mar-02-23 08:00AM	Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy (GlobeNewswire)
Jan-31-23 01:30PM	Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI) (ACCESSWIRE)
01:09PM	Loading…
01:09PM	Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement (GlobeNewswire)
Jan-27-23 11:58AM	Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules (GlobeNewswire) -10.97%
Nov-10-22 04:10PM	Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire) +12.23%
Nov-08-22 12:26PM	Avenue Therapeutics Buys Baergic Bio, Beefs Up Central Nervous System-Focused Portfolio (Benzinga)
08:30AM	Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A 2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders (GlobeNewswire)
Oct-12-22 10:25AM	Aegis Capital Corp. Acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI) (ACCESSWIRE) -10.56%
Oct-11-22 02:15PM	Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering (GlobeNewswire) +10.08%
Oct-06-22 11:00PM	Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering (GlobeNewswire) -25.74%
Oct-03-22 08:00AM	Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer (GlobeNewswire) +14.19%
Sep-23-22 08:51AM	Avenue Therapeutics Announces Reverse Stock Split, Regulatory Update For Lead Its Pain Candidate (Benzinga) -31.82%
Sep-22-22 04:25PM	Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA (GlobeNewswire) +105.90%
Mar-31-22 07:30AM	Abeona Therapeutics Announces Strategy Update and 2021 Financial Results (GlobeNewswire) -6.29%
Feb-16-22 08:20AM	FDA's AdComm Says Avenue Therapeutics Submitted Insufficient Data On IV Tramadol (Benzinga) -48.69%
Feb-15-22 10:00PM	Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol (GlobeNewswire)
07:05AM	Avenue Therapeutics Stock Trading Halted Today (GlobeNewswire)
02:15PM	Loading…
Dec-15-21 02:15PM	Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI) (ACCESSWIRE) -10.77%
12:00PM	Avenue Therapeutics Announces Closing of Public Offering of Common Stock (GlobeNewswire)
Dec-12-21 08:00PM	Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
Nov-29-21 08:00AM	Avenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol NDA Tentatively Scheduled for February 15, 2022 (GlobeNewswire) +53.15%
Nov-17-21 09:30AM	Avenue Therapeutics Announces Exercise and Closing of Underwriters Over-Allotment Option (GlobeNewswire)
Nov-12-21 10:40AM	Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI) (ACCESSWIRE)
09:20AM	Avenue Therapeutics Announces Closing of Public Offering of Common Stock (GlobeNewswire)
Nov-09-21 09:30PM	Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -8.14%
Oct-25-21 07:00AM	Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs (GlobeNewswire) +25.40%
Aug-26-21 11:04AM	Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study (Zacks)
Jun-21-21 08:04AM	Mondays Pre-Market: Heres What You Need to Know Before the Market Opens (TipRanks)
Jun-14-21 08:42AM	Mondays Pre-Market: Heres What You Need to Know Before the Market Opens (TipRanks) -28.27%
07:44AM	CORRECTED-U.S. FDA declines to approve Avenue's painkiller again, shares drop (Reuters)
07:00AM	Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol (GlobeNewswire)
Apr-26-21 08:09AM	BioRad (BIO) to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-23-21 11:36PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (GlobeNewswire)
09:43AM	What's in Store for Perrigo (PRGO) This Earnings Season? (Zacks)
08:41AM	ResMed (RMD) to Report Q3 Earnings: What's in the Offing? (Zacks)
Apr-22-21 10:59AM	Integra (IART) to Report Q1 Earnings: What's in the Offing? (Zacks)
Apr-21-21 10:34PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (Newsfile) +16.37%
09:38AM	VITUS to Hurt Chemed (CHE) Q1 Earnings, Roto-Rooter to Aid (Zacks)
Apr-19-21 10:09PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (PR Newswire)
06:26AM	Avenue Therapeutics (ATXI) Sees Hammer Chart Pattern: Time to Buy? (Zacks)
Apr-16-21 11:25PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (ACCESSWIRE)
Apr-14-21 10:34PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (GlobeNewswire) -11.99%
Apr-13-21 11:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (PR Newswire) -23.77%
03:09PM	Why Fortress Biotech Stock Is Sinking Today (Motley Fool)
02:30PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Avenue Therapeutics, Inc. (ATXI) Investigation (ACCESSWIRE)
09:33AM	JAZZ's Xywav sNDA for Hypersomnia Gets FDA Priority Review (Zacks)
06:30AM	Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol (GlobeNewswire)
Apr-12-21 01:36AM	Is Avenue Therapeutics (NASDAQ:ATXI) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jan-11-21 11:32PM	How Much Of Avenue Therapeutics, Inc. (NASDAQ:ATXI) Do Institutions Own? (Simply Wall St.)
Jan-06-21 09:23AM	Is Avenue Therapeutics (ATXI) Stock a Buy For 2021? (Insider Monkey)
Dec-18-20 08:00AM	Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis (GlobeNewswire) +15.41%
08:00AM	Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network (GlobeNewswire)
Dec-17-20 04:27PM	Why Fortress Biotech Stock Jumped Today (Motley Fool) +47.70%
07:00AM	Avenue Therapeutics Provides Regulatory Update for IV Tramadol (GlobeNewswire)
Nov-13-20 05:28AM	Read This Before Selling Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares (Simply Wall St.)
Oct-28-20 07:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (ACCESSWIRE)
Oct-23-20 10:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (ACCESSWIRE)
Oct-14-20 08:58PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (PR Newswire)
10:10AM	Biotech Stock Roundup: REGN, GILD's Coronavirus News & Other Pipeline Updates (Zacks)
Oct-13-20 01:29PM	Avenue Therapeutics' Pain Drug Gets Complete Response Letter (Zacks) -14.57%
Oct-12-20 01:35PM	Avenue Therapeutics Sinks As FDA Rejects Opioid Pain Drug On Safety Concerns (Benzinga) -58.97%
12:45PM	Why Fortress Biotech Stock Is Plunging Today (Motley Fool)
10:47AM	Why Fortress Biotech's Stock Is Trading Lower Today (Benzinga)
06:30AM	Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol (GlobeNewswire)
Sep-09-20 08:00AM	Avenue Therapeutics Announces Publication of a Review of IV Tramadol (GlobeNewswire)
Aug-17-20 10:33AM	Avenue Therapeutics (ATXI) Misses Earnings Estimates in Q2 (Zacks)
Aug-14-20 07:30AM	Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-04-20 12:53PM	What's in Store for Avenue Therapeutics (ATXI) in Q2 Earnings? (Zacks)
Jul-28-20 05:50PM	Avenue Therapeutics, Inc. (ATXI) Dips More Than Broader Markets: What You Should Know (Zacks)
Jul-22-20 05:50PM	Avenue Therapeutics, Inc. (ATXI) Stock Sinks As Market Gains: What You Should Know (Zacks)
Jul-21-20 08:30AM	Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results (GlobeNewswire)
Jul-16-20 05:50PM	Avenue Therapeutics, Inc. (ATXI) Dips More Than Broader Markets: What You Should Know (Zacks)
Jul-09-20 05:50PM	Avenue Therapeutics, Inc. (ATXI) Dips More Than Broader Markets: What You Should Know (Zacks)
11:30AM	Is Avenue Therapeutics (ATXI) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-07-20 11:50AM	Pacira (PCRX) Provides Preliminary Results for Second Quarter (Zacks)
Jun-29-20 08:30AM	Fortress Biotech Added to Russell 3000® Index (GlobeNewswire)
Jun-25-20 08:44AM	Veru (VERU) Soars: Stock Adds 6.9% in Session (Zacks)
Jun-24-20 12:00PM	Avenue Therapeutics, Inc. (ATXI) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
11:18AM	New Strong Buy Stocks for June 24th (Zacks)
Jun-23-20 10:38AM	Avenue Therapeutics' Shares March Higher, Can It Continue? (Zacks)
Jun-18-20 10:12AM	Aclaris Gets FDA Nod to Start Investigator-led Coronavirus Study (Zacks)
08:50AM	NGM Biopharmaceuticals (NGM) Soars: Stock Adds 7.8% in Session (Zacks)
Jun-17-20 11:30AM	Is Avenue Therapeutics (ATXI) Outperforming Other Medical Stocks This Year? (Zacks)
Jun-16-20 08:37AM	Provention Bio (PRVB) Looks Good: Stock Adds 8.6% in Session (Zacks)
Jun-15-20 10:00AM	Zacks.com featured highlights include: Frontline, iClick Interactive Asia, Avenue Therapeutics, ProQR Therapeutics and BJ???s Wholesale Club (Zacks)
Jun-11-20 08:55AM	NantHealth (NH) Looks Good: Stock Adds 9.1% in Session (Zacks)
08:41AM	Otonomy (OTIC) in Focus: Stock Moves 6.1% Higher (Zacks)

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fortress Biotech, Inc.	10% Owner	Sep 08	Buy	0.72	418,410	301,255	1,032,390	Sep 12 09:02 AM
ROSENWALD LINDSAY A MD	Director	Sep 08	Buy	0.72	348,675	251,046	354,318	Sep 12 09:03 AM
InvaGen Pharmaceuticals, Inc.	10% Owner	Oct 11	Sale	7.71	388,888	2,999,882	0	Oct 13 08:52 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATXI | Avenue Therapeutics, Inc.

Upgrade your FINVIZ experience